Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Group 1 - Erasca is a precision oncology company focusing on therapies targeting specific cancer-related mutations, particularly through the RAS/MAPK pathways [1] - The company has a relatively late-stage pipeline with its main drug candidate, Naporafenib [1]